UNSPSC 51413303: Alprostadil alfadex

This classification denotes a prostaglandin analogue with the molecular formula C20H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5TD010360, chemically known as prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11a,13e,15s)-, but more generally known as alprostadil alfadex, which bears US NIH Compound Identifier 11954014. European Medicines Agency schedules alprostadil alfadex or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05372MIG.

Most nations, for tariff purposes, schedule alprostadil alfadex under HS 29375000. SMILES: CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O.

UNSPSC 51413303 Alprostadil alfadex is a Commodity code that encompasses injectable pharmaceutical products used in emergency medical services and health system operations. State and local governments procure these medications through direct-purchase contracts with manufacturers and authorized wholesalers to stock emergency treatment kits, acute-care facilities, and emergency response services. The issuing bodies soliciting under this code include municipal fire and rescue departments, state health agencies, and regional cooperative purchasing alliances. Recent opportunities show cities and their emergency services as primary end-users, while state agencies and multi-jurisdictional cooperative purchasing vehicles act as procurement administrators sourcing generic pharmaceuticals and specialty injectables for distributed state and local networks.

The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26P00188) for Tampa Fire Rescue with a response date of April 8, 2026 and estimated contract value of $40,000.00, requiring four specific medication line items including epinephrine and diltiazem injectables, with a Small Local Business Enterprise sheltered-market designation and a 5 percent bid discount available. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, requiring vendors to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Recent activity concentrates in Florida, Minnesota, Texas, and Oregon, with municipal emergency services and state health agencies driving demand for injectable medications through both single-jurisdictional and multi-state cooperative procurement vehicles.